CpG island methylator phenotype of myelodysplastic syndrome identified through genome-wide profiling of DNA methylation and gene expression

British Journal of Haematology

Volumn 165, Issue 5, 2014, Pages 649-658

  Zhao, Xiaoli ^a   Yang, Feng ^b   Li, Shuang ^a   Liu, Meixia ^b   Ying, Shaoxu ^b   Jia, Xiaodong ^b   Wang, Xiaoqin ^a  

^a FUDAN UNIVERSITY   (China)

^b SHANGHAI MUNICIPAL CENTER FOR DISEASE CONTROL AND PREVENTION   (China)

Author keywords

CpG island methylator phenotype; Diagnosis; Methylation; Myelodysplastic syndrome; Prognosis

Indexed keywords

4 AMINOBUTYRATE AMINOTRANSFERASE; FAS ASSOCIATED DEATH DOMAIN PROTEIN; MESSENGER RNA;

ABAT GENE; ADULT; ARTICLE; CONTROLLED STUDY; CPG ISLAND METHYLATOR PHENOTYPE; DAPP1 GENE; DNA METHYLATION; FADD GENE; FEMALE; GENE EXPRESSION; GENETIC ASSOCIATION; GENETIC SCREENING; GENETIC SELECTION; HUMAN; HUMAN TISSUE; LRRFIP1 GENE; MAJOR CLINICAL STUDY; MALE; MARKER GENE; MICROARRAY ANALYSIS; MYELODYSPLASTIC SYNDROME; OVERALL SURVIVAL; PHENOTYPE; PLBD1 GENE; PRIORITY JOURNAL; PROGNOSIS; REAL TIME POLYMERASE CHAIN REACTION; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SMPD3 GENE; SURVIVAL RATE; AGED; CASE CONTROL STUDY; CPG ISLAND; GENE EXPRESSION PROFILING; GENETICS; KAPLAN MEIER METHOD; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; PROCEDURES;

AGED; CASE-CONTROL STUDIES; CPG ISLANDS; DNA METHYLATION; FEMALE; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENOME-WIDE ASSOCIATION STUDY; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; PHENOTYPE; PROGNOSIS; RNA, MESSENGER; SENSITIVITY AND SPECIFICITY;

EID: 84900467861     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/bjh.12811     Document Type: Article

References (51)

1. Abe, M., Watanabe, N., McDonell, N., Takato, T., Ohira, M., Nakagawara, A. & Ushijima, T. (2008) Identification of genes targeted by CpG island methylator phenotype in neuroblastomas, and their possible integrative involvement in poor prognosis. Oncology, 74, 50-60.
2. Arai, E., Chiku, S., Mori, T., Gotoh, M., Nakagawa, T., Fujimoto, H. & Kanai, Y. (2012) Single-CpG-resolution methylome analysis identifies clinicopathologically aggressive CpG island methylator phenotype clear cell renal cell carcinomas. Carcinogenesis, 33, 1487-1493.
3. Ashburner, M., Ball, C.A., Blake, J.A., Botstein, D., Butler, H., Cherry, J.M., Davis, A.P., Dolinski, K., Dwight, S.S. & Eppig, J.T. (2000) Gene ontology: tool for the unification of biology. Nature Genetics, 25, 25-29.
4. Berman, B.P., Weisenberger, D.J., Aman, J.F., Hinoue, T., Ramjan, Z., Liu, Y., Noushmehr, H., Lange, C.P.E., van Dijk, C.M., Tollenaar, R.A.E.M., Van Den Berg, D. & Laird, P.W. (2011) Regions of focal DNA hypermethylation and long-range hypomethylation in colorectal cancer coincide with nuclear lamina-associated domains. Nature Genetics, 44, 40-46.
5. Chen, H.-Y., Zhu, B.-H., Zhang, C.-H., Yang, D.-J., Peng, J.-J., Chen, J.-H., Liu, F.-K. & He, Y.-L. (2012) High CpG island methylator phenotype is associated with lymph node metastasis and prognosis in gastric cancer. Cancer Science, 103, 73-79.
6. Demircan, B., Dyer, L.M., Gerace, M., Lobenhofer, E.K., Robertson, K.D. & Brown, K.D. (2009) Comparative epigenomics of human and mouse mammary tumors. Genes, Chromosomes and Cancer, 48, 83-97.
7. Fan, R., Zhang, L.-Y., Wang, H., Yang, B., Han, T., Zhao, X.-L., Wang, W., Wang, X.-Q. & Lin, G.-W. (2012) Methylation of the cpg island near Sox7 gene promoter is correlated with the poor prognosis of patients with myelodysplastic syndrome. Tohoku Journal of Experimental Medicine, 227, 119-128.
8. Fenaux, P. & Ades, L. (2013) How we treat lower-risk myelodysplastic syndromes. Blood, 121, 4280-4286.
9. Friedrich, M.G., Chandrasoma, S., Siegmund, K.D., Weisenberger, D.J., Cheng, J.C., Toma, M.I., Huland, H., Jones, P.A. & Liang, G. (2005) Prognostic relevance of methylation markers in patients with non-muscle invasive bladder carcinoma. European Journal of Cancer, 41, 2769-2778.
10. Friedrich, M.G., Toma, M.I., Chun, J.K.H.F., Steuber, T., Budäus, L., Isbarn, H. & Huland, H. (2007) DNA-Methylierung in der urindiagnostik und als prognosemarker beim urothelkarzinom der harnblase. Der Urologe, 46, 761-768.
11. Gloss, B.S., Patterson, K.I., Barton, C.A., Gonzalez, M., Scurry, J.P., Hacker, N.F., Sutherland, R.L., O'Brien, P.M. & Clark, S.J. (2012) Integrative genome-wide expression and promoter DNA methylation profiling identifies a potential novel panel of ovarian cancer epigenetic biomarkers. Cancer Letters, 318, 76-85.
12. Goodell, M.A. & Godley, L.A. (2013) Perspectives and future directions for epigenetics in hematology. Blood, 121, 5131-5137.
13. Greenberg, P., Cox, C., LeBeau, M.M., Fenaux, P., Morel, P., Sanz, G., Sanz, M., Vallespi, T., Hamblin, T. & Oscier, D. (1997) International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood, 89, 2079-2088.
14. Hansen, K.D., Timp, W., Bravo, H.C., Sabunciyan, S., Langmead, B., McDonald, O.G., Wen, B., Wu, H., Liu, Y., Diep, D., Briem, E., Zhang, K., Irizarry, R.A. & Feinberg, A.P. (2011) Increased methylation variation in epigenetic domains across cancer types. Nature Genetics, 43, 768-775.
15. Jaffe, E.S., Harris, N.L., Stein, H. & Vardiman, J.W. (2001) Tumours of haematopoietic and lymphoid tissues, WHO Classification of Tumours. World Health Organization, Geneva.
16. Jiang, Y., Hatzi, K. & Shaknovich, R. (2013) Mechanisms of epigenetic deregulation in lymphoid neoplasms. Blood, 121, 4271-4279.
17. Kaiser, M.F., Johnson, D.C., Wu, P., Walker, B.A., Brioli, A., Mirabella, F., Wardell, C.P., Melchor, L., Davies, F.E. & Morgan, G.J. (2013) Global methylation analysis identifies prognostically important epigenetically inactivated tumor suppressor genes in multiple myeloma. Blood, 122, 219-226.
18. Kanehisa, M. & Goto, S. (2000) KEGG: kyoto encyclopedia of genes and genomes. Nucleic acids research, 28, 27-30.
19. Khin, S.S., Kitazawa, R., Kondo, T., Idei, Y., Fujimoto, M., Haraguchi, R., Mori, K. & Kitazawa, S. (2011) Epigenetic alteration by DNA promoter hypermethylation of genes related to transforming growth factor-β (TGF-β) signaling in cancer. Cancers, 3, 982-993.
20. Leo, E., Mancini, M., Aluigi, M., Castagnetti, F., Martinelli, G., Barbieri, E. & Santucci, M.A. (2012) DNA hypermethylation promotes the low expression of pro-apoptoticBCL2L11associated withBCR-ABL1fusion gene of chronic myeloid leukaemia. British Journal of Haematology, 159, 373-376.
21. Liu, J.-B. (2011) CpG island methylator phenotype in plasma is associated with hepatocellular carcinoma prognosis. World Journal of Gastroenterology, 17, 4718.
22. Malzkorn, B., Wolter, M., Riemenschneider, M.J. & Reifenberger, G. (2011) Unraveling the glioma epigenome-from molecular mechanisms to novel biomarkers and therapeutic targets. Brain Pathology, 21, 619-632.
23. Marsit, C.J., Houseman, E.A., Christensen, B.C., Eddy, K., Bueno, R., Sugarbaker, D.J., Nelson, H.H., Karagas, M.R. & Kelsey, K.T. (2006) Examination of a CpG island methylator phenotype and implications of methylation profiles in solid tumors. Cancer Research, 66, 10621-10629.
24. Marsit, C.J., Houseman, E.A., Nelson, H.H. & Kelsey, K.T. (2008) Genetic and epigenetic tumor suppressor gene silencing are distinct molecular phenotypes driven by growth promoting mutations in nonsmall cell lung cancer. Journal of Cancer Epidemiology, 2008, 1-8.
25. Min, B.-H., Bae, J., Lee, E., Yu, H., Kim, Y.-H., Chang, D., Kim, H., Park, C., Lee, S.-H., Kim, K.-M. & Kang, G. (2011) The CpG island methylator phenotype may confer a survival benefit in patients with stage II or III colorectal carcinomas receiving fluoropyrimidine-based adjuvant chemotherapy. BMC Cancer, 11, 344.
26. Mohamedali, A.M., Alkhatabi, H., Kulasekararaj, A., Shinde, S., Mian, S., Malik, F., Smith, A.E., Gäken, J. & Mufti, G.J. (2013) Utility of peripheral blood for cytogenetic and mutation analysis in myelodysplastic syndrome. Blood, 122, 4.
27. Moribe, T., Iizuka, N., Miura, T., Kimura, N., Tamatsukuri, S., Ishitsuka, H., Hamamoto, Y., Sakamoto, K., Tamesa, T. & Oka, M. (2009) Methylation of multiple genes as molecular markers for diagnosis of a small, well-differentiated hepatocellular carcinoma. International Journal of Cancer, 125, 388-397.
28. Ogino, S., Kawasaki, T., Kirkner, G.J., Loda, M. & Fuchs, C.S. (2006) CpG island methylator phenotype-low (CIMP-Low) in colorectal cancer: possible associations with male sex and KRAS mutations. The Journal of Molecular Diagnostics, 8, 582-588.
29. Ogino, S., Kawasaki, T., Kirkner, G.J., Kraft, P., Loda, M. & Fuchs, C.S. (2007) Evaluation of markers for CpG island methylator phenotype (CIMP) in colorectal cancer by a large population-based sample. The Journal of Molecular Diagnostics, 9, 305-314.
30. Ohka, F., Natsume, A., Motomura, K., Kishida, Y., Kondo, Y., Abe, T., Nakasu, Y., Namba, H., Wakai, K. & Fukui, T. (2011) The global DNA methylation surrogate LINE-1 methylation is correlated with MGMT promoter methylation and is a better prognostic factor for glioma. PLoS ONE, 6, e23332.
31. Ramos, F., Fernández-Ferrero, S., Suárez, D., Barbón, M., Rodríguez, J.A., Gil, S., Megido, M., López, N., Del Cañizo, C. & Orfao, A. (1999) Myelodysplastic syndrome: a search for minimal diagnostic criteria. Leukemia Research, 23, 283-290.
32. Ren, J., Singh, B.N., Huang, Q., Li, Z., Gao, Y., Mishra, P., Hwa, Y.L., Li, J., Dowdy, S.C. & Jiang, S.-W. (2011) DNA hypermethylation as a chemotherapy target. Cellular Signalling, 23, 1082-1093.
33. Revill, K., Wang, T., Lachenmayer, A., Kojima, K., Harrington, A., Li, J., Hoshida, Y., Llovet, J.M. & Powers, S. (2013) Genome-wide methylation analysis and epigenetic unmasking identify tumor suppressor genes in hepatocellular carcinoma. Gastroenterology, 145, e1425.
34. del Rey, M., O'Hagan, K., Dellett, M., Aibar, S., Colyer, H.A.A., Alonso, M.E., Díez-Campelo, M., Armstrong, R.N., Sharpe, D.J., Gutiérrez, N.C., García, J.L., De Las Rivas, J., Mills, K.I. & Hernández-Rivas, J.M. (2012) Genome-wide profiling of methylation identifies novel targets with aberrant hypermethylation and reduced expression in low-risk myelodysplastic syndromes. Leukemia, 27, 610-618.
35. Roman-Gomez, J. (2005) Lack of CpG island methylator phenotype defines a clinical subtype of t-cell acute lymphoblastic leukemia associated with good prognosis. Journal of Clinical Oncology, 23, 7043-7049.
36. Roman-Gomez, J. (2006) CpG island methylator phenotype redefines the prognostic effect of T(12;21) in childhood acute lymphoblastic leukemia. Clinical Cancer Research, 12, 4845-4850.
37. Roman-Gomez, J., Jimenez-Velasco, A., Barrios, M., Prosper, F., Heiniger, A., Torres, A. & Agirre, X. (2007) Poor prognosis in acute lymphoblastic leukemia may relate to promoter hypermethylation of cancer-related genes. Leukemia & Lymphoma, 48, 1269-1282.
38. Roossink, F., Jong, S., Wisman, G.B.A., Zee, A.G.J. & Schuuring, E. (2012) DNA hypermethylation biomarkers to predict response to cisplatin treatment, radiotherapy or chemoradiation: the present state of art. Cellular Oncology, 35, 231-241.
39. Samowitz, W.S., Albertsen, H., Herrick, J., Levin, T.R., Sweeney, C., Murtaugh, M.A., Wolff, R.K. & Slattery, M.L. (2005) Evaluation of a large, population-based sample supports a CpG island methylator phenotype in colon cancer. Gastroenterology, 129, 837-845.
40. Sánchez-Carbayo, M. (2012) Hypermethylation in bladder cancer: biological pathways and translational applications. Tumor Biology, 33, 347-361.
41. Sandoval, J., Heyn, H.A., Moran, S., Serra-Musach, J., Pujana, M.A., Bibikova, M. & Esteller, M. (2011) Validation of a DNA methylation microarray for 450, 000 CpG sites in the human genome. Epigenetics, 6, 692-702.
42. Shaffer, L.G., Slovak, M.L. & Campbell, L.J. (2009) An International System for Human Cytogenetic Nomenclature (2009). International Standing Committee on Human Cytogenetic Nomenclature, Karger, Basel.
43. Shen, L., Kantarjian, H., Guo, Y., Lin, E., Shan, J., Huang, X., Berry, D., Ahmed, S., Zhu, W., Pierce, S., Kondo, Y., Oki, Y., Jelinek, J., Saba, H., Estey, E. & Issa, J.P.J. (2009) DNA methylation predicts survival and response to therapy in patients with myelodysplastic syndromes. Journal of Clinical Oncology, 28, 605-613.
44. Shinjo, K., Okamoto, Y., An, B., Yokoyama, T., Takeuchi, I., Fujii, M., Osada, H., Usami, N., Hasegawa, Y., Ito, H., Hida, T., Fujimoto, N., Kishimoto, T., Sekido, Y. & Kondo, Y. (2012) Integrated analysis of genetic and epigenetic alterations reveals CpG island methylator phenotype associated with distinct clinical characters of lung adenocarcinoma. Carcinogenesis, 33, 1277-1285.
45. Sullivan, L., Murphy, T.M., Barrett, C., Loftus, B., Thornhill, J., Lawler, M., Hollywood, D., Lynch, T. & Perry, A.S. (2012) IGFBP7 promoter methylation and gene expression analysis in prostate cancer. The Journal of Urology, 188, 1354-1360.
46. Wang, H., Wang, X.-Q., Xu, X.-P. & Lin, G.-W. (2010) ID4 methylation predicts high risk of leukemic transformation in patients with myelodysplastic syndrome. Leukemia Research, 34, 598-604.
47. Warth, A., Kloor, M., Schirmacher, P. & Bläker, H. (2011) Genetics and epigenetics of small bowel adenocarcinoma: the interactions of CIN, MSI, and CIMP. Modern Pathology, 24, 564-570.
48. Weisenberger, D.J., Siegmund, K.D., Campan, M., Young, J., Long, T.I., Faasse, M.A., Kang, G.H., Widschwendter, M., Weener, D., Buchanan, D., Koh, H., Simms, L., Barker, M., Leggett, B., Levine, J., Kim, M., French, A.J., Thibodeau, S.N., Jass, J., Haile, R. & Laird, P.W. (2006) CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer. Nature Genetics, 38, 787-793.
49. Xu, Y., Hu, B., Choi, A.J., Gopalan, B., Lee, B.H., Kalady, M.F., Church, J.M. & Ting, A.H. (2011) Unique DNA methylome profiles in CpG island methylator phenotype colon cancers. Genome Research, 22, 283-291.
50. Zhang, Q.-Y., Yi, D.-Q., Zhou, L., Zhang, D.-H. & Zhou, T.-M. (2011) Status and significance of CpG island methylator phenotype in endometrial cancer. Gynecologic and Obstetric Investigation, 72, 183-191.
51. Zhao, Y., Zhou, H., Ma, K., Sun, J., Feng, X., Geng, J., Gu, J., Wang, W., Zhang, H. & He, Y. (2013) Abnormal methylation of seven genes and their associations with clinical characteristics in early stage non-small cell lung cancer. Oncology Letters, 5, 1211-1218.